NMC Guidelines For Competency-Based Training Programme For DM Medical Genetics
Genetic Correction Of Sickle Cell Disease: Insights Using Transgenic Mouse Models
Bertles, J.F. & Milner, P.F. Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia. J. Clin. Invest. 47, 1731– 1741 (1968).
Charache, S. Et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 332, 1317–1322 (1995).
Dover, G.J., Brusilow, S. & Charache, S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84, 339–343 (1994).
McCaffrey, P.G., Newsome, D.A., Fibach, E., Yoshida, M. & Su, M.S.-S., Induction of γ-globin by histone deacetylase inhibitors. Blood 90, 2075–2083 (1997).
Perrine, S.P. Et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N. Engl. J. Med. 328, 81–86 (1993).
Stamatoyannopoulos, G. Et al. Fetal hemoglobin induction by acetate, a product of butyrate catabolism. Blood 84, 3198– 3204 (1994).
Popp, R.A. Et al. A transgenic mouse model of hemoglobin S Antilles disease. Blood 89, 4204–4212 ( 1997).
Paszty, C. Et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278, 876 –878 (1997).
Ryan, T.M., Ciavatta, D.J. & Townes, T.M. Knockout-transgenic mouse model of sickle cell disease . Science 278, 873–876 (1997).
Fabry, M.E. Et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity . Blood 86, 2419–2428 (1995).
Greaves, D.R. Et al. A transgenic mouse model of sickle cell disorder. Nature 343, 183–185 ( 1990).
Trudel, M. Et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J. 10, 3157–3165 (1991).
De Paepe, M.E. & Trudel, M. The transgenic SAD mouse: a model of human sickle cell glomerulopathy. Kidney Int. 46, 1337–1345 ( 1994).
Blouin, M.-J., De Paepe, M. & Trudel, M. Altered hematopoiesis in murine sickle cell disease . Blood 94, 1451–1459 (1999).
Trudel, M. Et al. Sickle cell disease of transgenic SAD mice. Blood 84, 3189–3197 ( 1994).
De Franceschi, L., Saadane, N., Trudel, M., Brugnara, C. & Beuzard, Y. Treatment with oral clotrimazole blocks Ca2+-activated K+transport and reverses erythrocytes dehydration in transgenic SAD mice. J. Clin. Invest. 93, 1670–1676 (1994).
Enver, T., Ebens, A.J., Forrester, W.C. & Stamatoyannopoulos, G. The human β-globin locus activation region alters the developmental fate of a human fetal globin gene in transgenic mice. Proc. Natl. Acad. Sci. USA 86, 7033–7037 ( 1989).
Stamatoyannopoulos, G., Josephson, B., Zhang, J.-W. & Li, Q. Developmental regulation of human gamma-globin genes in transgenic mice. Mol. Cell. Biol. 13, 7636–7644 (1993).
Powars, D.R., Weiss, J.N., Chan, L.S. & Schroeder, W.A. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 63, 921–926 (1984).
Serjeant, G.R. Irreversibly sickled cells and splenomegaly in sickle-cell anaemia. Br. J. Haematol. 19, 635–641 (1970).
Platt, O.S. Et al. Pain in sickle cell disease: Rates and risk factors. N. Engl. J. Med. 325, 11–16 (1991).
Platt, O.S. Et al. Mortality in sickle cell disease: Life expectancy and risk factors for early death. N. Engl. J. Med. 330, 1639–1644 (1994).
Noguchi, C.T., Rodgers, G.P., Serjeant, G. & Schechter, A.N. Levels of fetal hemoglobin necessary for treatment of sickle cell disease . N. Engl. J. Med. 318, 96– 99 (1988).
Croizat, H. & Nagel, R.L. Circulating BFU-E in sickle cell anemia: Relationship to percent fetal hemoglobin and BPA-like activity. Exp. Hematol. 16, 946–949 (1988).
Croizat, H., Billett, H.H. & Nagel, R.L. Heterogeneity in the properties of burst-forming units of erythroid lineage in sickle cell anemia: DNA synthesis and burst-promoting activity production is related to peripheral hemoglobin F levels. Blood 75, 1006–1010 ( 1990).
Croizat, H. & Nagel, R.L. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am. J. Hematol. 60, 105–115 ( 1999).
Alter, B.P., Goff, S.C., Efremov, G.D., Gravely, M.E. & Huisman, T.H.J. Globin chain electrophoresis: A new approach to the determination of the Gγ/Aγ ratio in fetal haemoglobin and to studies of globin synthesis . Br. J. Haematol. 44, 527– 534 (1980).
Schroeder, W.A., Shelton, J.B., Shelton, J.R. & Auynh, V. High performance liquid chromatographic separation of the globin chains of non-human hemoglobins. Hemoglobin 9, 461 –482 (1985).
Ou, C.-N. & Rognerud, C.L. Rapid analysis of hemoglobin variants by cation-exchange HPLC. Clin. Chem. 39, 820–824 (1993).
Trudel, M. & Costantini, F. A 3′ enhancer contributes to the stage-specific expression of the human β-globin gene. Genes Dev. 1, 954–961 ( 1987).
Trudel, M., Magram, J., Bruckner, L. & Costantini, F. UpstreamGγ-globin and downstream β-globin gene domain in human erythroid cells. Mol. Cell. Biol. 7, 4024 –4029 (1987).
Stamatoyannopoulos, G. Et al. Monoclonal antibodies specific for globin chains. Blood 61, 530–539 ( 1983).
Corash, L.M., Piomelli, S., Chen, H.C., Seaman, C. & Gross, E. Separation of erythrocytes according to age on a simplified density gradient. J. Lab. Clin. Med. 84, 147–151 (1974).
Bunn, H.F. & Forget, B.G. In Hemoglobin: Molecular Genetic and Clinical Aspects 690 (W.B. Saunders, Philadelphia, 1986).
Kim, Y.R. & Ornstein, L. Isovolumentric sphering of erythrocytes for more accurate and precise cell measurements by flow cytometry. Cytometry 3, 419–427 ( 1983).
Tycko, D.H., Metz, M.H., Epstein, E.A. & Grinbaum, A. Flow cytometric light scattering measurement of red cell volume and hemoglobin concentration. Appl. Optics 24, 1355– 1365 (1985).
Mohandas, N. Et al. Accurate and independent measurement of volume and hemoglobin concentration of individual red cells by laser light scattering. Blood 68, 506–513 ( 1986).
Mohandas, N. Et al. Automated quantitation of cell density distribution and hyperdense cell fraction in RBC disorders. Blood 74, 442–447 (1989).
Brugnara, C. Et al. Automated reticulocyte counting and measurement of reticulocyte cellular indices: Evaluation of the Miles H*3 blood analyzer . Am. J. Clin. Pathol. 102, 623– 632 (1994).
Human Genetics: Concepts And Application
Because of natural selection, different alleles are more likely to confer a survival advantage in different environments. Cycles of infectious disease prevalence and virulence often reflect natural selection.
Balanced PolymorphismIf natural selection eliminates individuals with detrimental phenotypes from a population, then why do harmful mutant alleles persist in a gene pool? A disease can remain prevalent when heterozygotes have some other advantage over individuals who have two copies of the wild type allele. When carriers have advantages that allow a detrimental allele to persist in a population, balanced polymorphism is at work. This form of polymorphism often entails heterozygosity for an inherited illness that protects against an infectious illness. Examples are fascinating.
Sickle Cell DiseaseSickle Cell disease is an autosomal recessive disorder that causes anemia, joint pain, a swollen spleen, and frequent, severe infections. It illustrates balanced polymorphism because carriers are resistant to malaria, an infection by the parasite Plasmodium falciparum that causes cycles of chills and fever. The parasite spends the first stage of its life cycle in the salivary glands of the mosquito Anopheles gambiae. When an infected mosquito bites a human, the malaria parasite enters the red blood cells, which transport it to the liver. The red blood cells burst, releasing the parasite throughout the body.
In 1949, British geneticist Anthony Allison found that the frequency of sickle cell carriers in tropical Africa was higher in regions where malaria raged all year long. Blood tests from children hospitalized with malaria found that nearly all were homozygous for the wild type of sickle cell allele. The few sickle cell carriers among them had the mildest cases of malaria. Was the presence of malaria somehow selecting for the sickle cell allele by felling people who did not inherit it? The fact that sickle cell disease is far less common in the United States, where malaria is rare, supports the idea that sickle cell heterozygosity provides a protective effect.
Further evidence of a sickle cell carrier's advantage in a malaria-ridden environment is the fact that the rise of sickle cell disease parallels the cultivation of crops that provide breeding grounds for Anopheles mosquitoes. About 1,000 B.C., Malayo-Polynesian sailors from southeast Asia traveled in canoes to East Africa, bringing new crops of bananas, yams, taros, and coconuts. When the jungle was cleared to grow these crops, the open space provided breeding ground for mosquitoes. The insects, in turn, offered a habitat for part of the life cycle of the malaria parasite.
The sickle cell gene may have been brought to Africa by people migrating from Southern Arabia and India, or it may have arisen by mutation directly in East Africa. However it happened, people who inherited one copy of the sickle cell allele had red blood cell membranes that did not admit the parasite. Carriers had more children and passed the protective allele to approximately half of them. Gradually, the frequency of the sickle cell allele in East Africa rose from 0.1 percent to a spectacular 45 percent in thirty-five generations. Carriers paid the price for this genetic protection, whenever two produced a child with sickle cell disease.
A cycle set in. Settlements with large numbers of sickle cell carriers escaped debilitating malaria. They were therefore strong enough to clear even more land to grow food- and support the disease-bearing mosquitoes. Even today, sickle cell disease is more prevalent in agricultural societies than among people who hunt and gather their food.
Glucose-6-Phosphate Dehydrogenase DeficiencyG6PD deficiency is a sex-linked enzyme deficiency that affects 400 million people worldwide. It causes life-threatening hemolytic anemia, in which red blood cells burst. However, it develops only under specific conditions- eating fava beans, inhaling certain types of pollen, taking certain drugs, or contracting certain infections. Studies on African children with severe malaria show that heterozygous females and hemizygous males for G6PD deficiency are underrepresented. This suggests that inheriting the enzyme deficiency gene somehow protects against malaria.
The fact that G6PD deficiency is sex-linked introduces a possibility we do not see with sickle cell disease, which is autosomal recessive. Because both heterozygotes and hemizygotes are selected for, the mutant allele should eventually predominate in a malaria-exposed population. However, this doesn't happen- there are still males hemizygous and females homozygous for the wild type allele. The reason again relates to natural selection. People with the enzyme deficiency- hemizygous males and homozygous females- are selected out of the population by the anemia. Therefore, natural selection acts in two directions on the hemizygous males- selecting for the mutant allele because it protects against malarial infection, yet selecting against it because an enzyme deficiency. This is the essence of balanced polymorphism.
PKUPhenylketnonuria is an inborn error of metabolism in which a missing enzyme causes the amino acid phenylalanine to build up, with devastating effects on the nervous system unless the individual follows a restrictive diet. Carriers of this autosomal recessive condition have elevated phenylalanine levels- levels that are not sufficiently high to cause symptoms, but that are high enough that they may have a protective effect during pregnancy. Physicians have observed that women who are PKU carriers have a much lower-than�average incidence of miscarriage. One theory is that excess phenylalanine somehow inactivates a poison, called ochratoxin A, that certain fungi produce and that is known to cause spontaneous abortion.
History provides the evidence that links PKU heterozygosity to protection against a fungal toxin. PKU is most common in Ireland and western Scotland, and many affected families living elsewhere trace their roots to this part of the world. If PKU carriers were most likely to have children than non-carriers because of the protective effects of the PKU gene, over time, the disease-causing allele would increase the population.
Tay-Sachs DiseaseCarrying Tay-Sachs disease may protect against tuberculosis (TB). In Ashkenazim populations, up to 11 percent of the people are Tay-Sachs carriers. During World War II, TB ran rampant in Eastern European Jewish settlements. Often, healthy relatives of children with Tay-Sachs disease did not contact TB, even when repeatedly exposed. The protection against TB that Tay-Sachs disease heterozygosity apparently offered remained among the Jewish people because they were prevented from leaving the ghettos. The mutant allele increased in frequency as TB selectively felled those who did not carry it and the carriers had children with each other. Genetic drift may also have helped isolate the Tay-Sachs allele, by chance, in groups of holocaust survivors. Precisely how lowered levels of the gene product, an enzyme called hexoseaminidase A, protect against TB isn't known.
Cystic FibrosisBalanced polymorphism may explain why cystic fibrosis is so common- the anatomical defect that underlies CF protects against diarrheal illnesses, such as cholera.
Cholera epidemics have left their mark on human populations, causing widespread death in just days. In the summer of 1831, an epidemic killed 10 percent of the population of St. Louis, and in 1991, an epidemic swept Peru. Cholera bacteria causes diarrhea, which rapidly dehydrates the body and can lead to shock and kidney and heart failure. The bacterium produces a toxin that opens chloride channels in the small intestine. As salt (NaCl) leaves the cells, water follows, in a natural chemical tendency to dilute the salt. Water rushing out of intestinal cells leaves the body as diarrhea.
In 1989, when geneticists identified the CF gene and described its protein product as a regulator of a chloride channel in certain secretory cells, a possible explanation for the prevalence of the inherited disorder emerged. Cholera opens chloride channels, letting chloride and water leave cells. The CFTR protein does just the opposite, closing chloride channels and trapping salt and water in cells, which dries out mucus and other secretions. A person with CF cannot contract cholera, because the toxin cannot open the chloride channels in the small intestine.
Carriers of CF enjoy the mixed blessing of a balanced polymorphism. They do not have enough abnormal chloride channels to cause the labored breathing and clogged pancreas of cystic fibrosis, but they do have enough of a defect to prevent the cholera from taking hold. During the devastating cholera epidemics that have peppered history, individuals carrying mutant CF alleles had a selective advantage, and they disproportionately transmitted those alleles to future generations. However, because CF arose in Western Europe and cholera in Africa, perhaps an initial increase in CF herterozygosity was a response to a different diarrheal infection.
Sickle Cell Disease
Sickle-cell disease (SCD), or sickle-cell anaemia (or anemia, SCA) or drepanocytosis, is an autosomal recessive genetic blood disorder with overdominance, characterized by red blood cells that assume an abnormal, rigid, sickle shape. Sickling decreases the cells' flexibility and results in a risk of various complications. The sickling occurs because of a mutation in the hemoglobin gene. Life expectancy is shortened. In 1994, in the US, the average life expectancy of persons with this condition was estimated to be 42 years in males and 48 years in females, but today, thanks to better management of the disease, patients can live into their 50s or beyond. In the UK, the current life expectancy is estimated to be 53–60 years of age.
Sickle-cell disease, usually presenting in childhood, occurs more commonly in people (or their descendants) from parts of tropical and sub-tropical regions where malaria is or was common. One-third of all indigenous inhabitants of Sub-Saharan Africa carry the gene, because in areas where malaria is common, there is a fitness benefit in carrying only a single sickle-cell gene (sickle cell trait). Those with only one of the two alleles of the sickle-cell disease, while not totally resistant, are more tolerant to the infection and thus show less severe symptoms when infected.
The prevalence of the disease in the United States is approximately 1 in 5,000, mostly affecting Americans of Sub-Saharan African descent, according to the National Institutes of Health. In the United States, about 1 out of 500 African-American children born will have sickle-cell anaemia.
Sickle-cell anaemia is the name of a specific form of sickle-cell disease in which there is homozygosity for the mutation that causes HbS. Sickle-cell anaemia is also referred to as "HbSS", "SS disease", "haemoglobin S" or permutations thereof. In heterozygous people, who have only one sickle gene and one normal adult haemoglobin gene, it is referred to as "HbAS" or "sickle cell trait". Other, rarer forms of sickle-cell disease include sickle-haemoglobin C disease (HbSC), sickle beta-plus-thalassaemia (HbS/β+) and sickle beta-zero-thalassaemia (HbS/β0). These other forms of sickle-cell disease are compound heterozygous states in which the person has only one copy of the mutation that causes HbS and one copy of another abnormal haemoglobin allele.
The term disease is applied, because the inherited abnormality causes a pathological condition that can lead to death and severe complications. Not all inherited variants of haemoglobin are detrimental, a concept known as genetic polymorphism.
Comments
Post a Comment